Magazine articles list

This year, for Childhood Cancer Awareness Month (CCAM), CCLG has been working hard to raise awareness of the long-term impact of childhood cancer and its treatments.

Jake Andrade was first diagnosed with leukaemia as a 13-year-old, before relapsing aged 19. Now 21, he tells us about the goals he set to help him through his second treatment and recovery, and how he has published a book to help other young people with cancer

The Little Princess Trust (LPT) forges important partnerships with other charities, such as CCLG, to further children’s cancer research. Its Chief Executive Phil Brace tells us how the LPT has come together with Cancer Research UK to help more young people access clinical trials.

Nicky Webb, is a clinical nurse specialist for the long-term follow-up of survivors of childhood cancer at the East Midlands Children and Young Person's Integrated Cancer Service. She is also a CCLG member and plays an active role in CCLG's specialist Late Effects Group.

Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania

LATCH Welsh Children’s Cancer Charity supports children and young people with cancer and their families who are under the care of the Children’s Hospital for Wales. As it celebrates its 40th anniversary, LATCH’s CEO, Menai Owen-Jones, reflects on its achievements over the past four decades.

Lillie Killick was 14 years old when diagnosed with leukaemia in 2010. Now 27, she tells us how some of the support she received after treatment helped to inspire her career choices

It’s not just the type of treatments that doctors look to improve, but the way they can be delivered so they are safer and more effective, too. We hear from two leading experts on already established advancements in eye cancer treatment, and a developing example of progress in brain tumour therapy.

First formed to establish clinical trials in childhood cancer, research has always been an integral part of CCLG’s work. Ellie Ellicott, CCLG Research Communications Executive, tells us more about its research journey and how the experiences of those that matter the most are helping shape future directions.